Pfizer has completed positive Phase 3 trials for LITFULO (ritlecitinib) in nonsegmental vitiligo and plans to submit global regulatory filings for it as a potential new oral systemic therapy for adults with the disease.
LITFULO is already approved for severe alopecia areata in multiple markets, including the U.S., EU, Canada, Japan, China, and the U.K., positioning Pfizer to challenge Incyte and AbbVie in the emerging oral JAK inhibitor space for vitiligo.
AbbVie’s upadacitinib (Rinvoq) has recently secured approval in nonsegmental vitiligo in the EU, while Incyte’s ruxolitinib (Opzelura) dominates the topical market, setting up a competitive landscape that Pfizer aims to disrupt with an oral systemic option.
Sources:
Pfizer Announces Positive Topline Phase 3 Results for LITFULO in ...
European Commission Approves Pfizer's LITFULO™ for Adolescents ...
Ritlecitinib for nonsegmental vitiligo
A New Era for Vitiligo Treatment
Vitiligo Drug Pipeline Analysis and Market Insights Updated
Ritlecitinib: First Approval - PMC - NIH
Litfulo, INN-ritlecitinib - EMA
215830Orig1s000 OTHER REVIEW(S) - accessdata.fda.gov
CENTER FOR DRUG EVALUATION AND RESEARCH
FDA and EMA Accept Pfizer Submissions for Ritlecitinib ...
Pfizer posts late-stage trial wins for vitiligo drug (PFE:NYSE)
News - 02 Jan `25 - 📌 Vitiligo Drug Pipeline Analysis - January 2026